Immuron

76 articles about Immuron

• Immuron Announces FDA Removed Clinical Hold on New Campylobacter ETEC Therapeutic Paves way for Clinical Trial Initiation

  5/8/2023

  Immuron Limited is pleased to announce that the US Naval Medical Research Center has received approval from the US Food and Drug Administration to proceed with the clinical evaluation of a new oral therapeutic targeting Campylobacter and Enterotoxigenic Escherichia coli developed in collaboration with Immuron.

• Immuron CEO, Steven Lydeamore to present at Coffee Microcaps

  5/2/2023

  Immuron Limited, an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases, is pleased to provide a copy of the presentation being made in Melbourne at Coffee Microcaps Conference by our Chief Executive Officer, Steven Lydeamore.

• Immuron Q3 FY23 Business Update Presentation

  4/19/2023

  Immuron Limited is pleased to provide the Q3 FY23 Investor Presentation for the business update webinar.

• Q3 FY23 Business Update Webinar Notification

  4/11/2023

  Immuron Limited is pleased to advise it will provide a business update for the quarter ended 31 March 2023.

• Immuron Q3 Sales reach 150% of 1H Sales

  4/6/2023

  Immuron Limited is pleased to announce the Q3 FY23 sales* results of its over-the-counter gastrointestinal and digestive health immune supplement Travelan® and Protectyn®.

• Immuron CEO, Steven Lydeamore to host an investor webinar

  2/15/2023

  Immuron Limited invites investors to join a live webcast hosted by Steven Lydeamore, CEO of Immuron Limited.

• Immuron US DoD Naval Medical Research Center responds to FDA Clinical Hold for New Campylobacter ETEC Therapeutic

  1/25/2023

  Immuron Limited today announces that a response letter has been submitted to the US Food and Drug Administration (FDA). Immuron has previously reported feedback was received from the FDA following a review of the Investigational New Drug (IND) application (ASX announcement July 26, 2022) of a new oral therapeutic targeting Campylobacter and ETEC developed in collaboration with Immuron.

• US Department of Defense Uniformed Services University Clinical Evaluation of Travelan™ Achieves 150 Recruitment Milestone

  1/18/2023

  Immuron Limited is pleased to provide shareholders and the market with a progress update on the US Department of Defense Uniformed Services University Clinical Evaluation of Travelan.

• Immuron Receives European Patent on Drug Composition to Treat Clostridioides difficile Associated Disease

  1/17/2023

  Immuron Limited is pleased to announce that has been granted a European Patent for compositions and methods for the treatment and/or prophylaxis of Clostridioides difficile associated disease.

• Immuron Receives FDA Approval for Travelan IND Application

  12/23/2022

  Immuron receives U.S. Food and Drug administration (FDA) approval for Travelan Investigational New Drug (IND) application.

• Immuron completes strategic investment in leading gut health biotech Ateria Health

  11/16/2022

  Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to announce that it completed a strategic investment in Ateria Health Limited, a U.K. based company that has developed ground-breaking product for the treatment of irritable bowel syndrome (IBS),

• Immuron CEO, Steven Lydeamore to present at AusBioInvest 2022

  10/26/2022

  Immuron Limited is pleased to provide investors with a copy of the presentation slide deck to be showcased at AusBioInvest 2022 in Perth, Australia on October 27, 2022, by our Chief Executive Officer, Steven Lydeamore.

• Immuron strategic investment in leading gut health biotech Ateria Health

  10/13/2022

  Immuron Limited is pleased to announce that it has signed a strategic investment and option agreement with Ateria Health Limited, a U.K. based company that has developed ground-breaking product for the treatment of irritable bowel syndrome.

• Immuron Executes Travelan Clinical Trial Agreement with US-based Pharmaron

  10/4/2022

  Immuron Limited is pleased to announce that it has executed a Master Service Agreement with US-based Pharmaron CPC, Inc. a Maryland Corporation located in Baltimore USA.

• Immuron Update on IMM-124E SARS-CoV-2 Research

  8/19/2022

  Immuron Limited announced that it has deprioritized SARS-CoV-2 research to focus on the clinical development of our more advanced stage therapeutic drug candidates.

• Immuron US DoD Naval Medical Research Center Receives feedback on IND Application for New Campylobacter ETEC Therapeutic

  7/26/2022

  Immuron Limited announced that the US Naval Medical Research Center has received feedback from the US Food and Drug Administration following a review of the Investigational New Drug application for a new oral therapeutic targeting Campylobacter and ETEC.

• Immuron North American Travelan® Sales up 494% and Global sales up 431%

  7/11/2022

  Immuron Limited is pleased to announce the FY22 sales results of its over-the-counter gastrointestinal and digestive health immune supplement Travelan® and Protectyn®.

• Immuron Receives European Patent Notification on Drug Composition to Treat Clostridioides difficile Associated Disease

  7/7/2022

  Immuron Limited is pleased to announce that it has received notification of the Intent to Grant a European Patent for compositions and methods for the treatment and/or prophylaxis of Clostridioides difficile associated disease.

• Immuron US DoD Naval Medical Research Center Submits IND Application for New Campylobacter ETEC Therapeutic

  5/11/2022

  Immuron Limited is pleased to announce that the US Naval Medical Research Center has submitted an Investigational New Drug application to the US Food and Drug Administration for a new oral therapeutic targeting Campylobacter and ETEC developed in collaboration with Immuron.

• US Department of Defense Uniformed Services University Clinical Evaluation of Travelan™

  5/9/2022

  Immuron Limited is pleased to provide shareholders and the market with a progress update on the planned clinical trial to evaluate the efficacy of Travelan® and two third party non-antibiotic products in Travelers’ Diarrhea